Cellphire has filed a notice of an exempt offering of securities to raise $8,000,000.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Cellphire is raising $8,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Mike Gaffney played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Cellphire
Cellphire Therapeutics, Inc. is a Rockville, Maryland-based biotechnology company developing next-generation therapeutics. The company is applying its proprietary cell stabilization technology to all cell types, including platelets, to develop lifesaving products. Its lead product, Thrombosomes, a freeze-dried hemostatic agent derived from human platelets, is currently in a Phase I clinical trial. Cellphires technology has potential applications across a wide range of medical applications from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine.
To learn more about Cellphire, visit http://www.cellphire.com/
Contact:
Mike Gaffney, Chief Executive Officer
240-268-2489
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.